Rolling out the HPV vaccine in the DRC
Why is this so important to DRC’s girls? . In the DRC, cervical cancer-related deaths are often linked to shortfalls in screening and treatment.
Following the recommendation of the National Immunization Technical Advisory Group (NITAG), the DRC will offer the quadrivalent vaccine (Gardasil?) to all girls aged 9 to 14 years, starting in 2026. A single dose of Gardasil protects against HPV types 6, 11, 16, and 18, which are responsible for about 70% of cervical cancer cases.
Catalyzing policy dialogue in support of the HPV vaccine
This has enabled the DRC to convene several multisectoral meetings involving the Ministries of Public Health, Prevention and Social Protection, National Education, Gender, and Youth, as well as the National Committee for Universal Health Coverage to discuss the roll out of vaccines and develop a roadmap for the integration of cervical cancer screening and treatment.
Also, with support from the Foundation, a Knowledge, Attitude and Practice (KAP) Study has been conducted by the World Bank, WHO and the University of Lubumbashi among young girls and their parents in the provinces of Kinshasa and Haut-Katanga to find out perceptions about the HPV vaccine and cervical cancer.
One-third of the KAP study survey respondents reported they did not feel the need to be vaccinated. This proportion was twice as high among girls aged 17 to 20 (45.7%) compared to parents of girls aged 9 to 17 (24.5%). The reasons differed between parents and girls. Girls felt less concerned about developing cervical cancer and had less information available. For parents, the lack of availability or organization of vaccination in health facilities were the primary reasons. It was found that less than 10% of participants had undergone cervical cancer screening.
One respondent noted “The best way to protect our children from this disease in their lives is to have them vaccinated against it, if the vaccine exists, because we know that vaccines protect people and prevent the onset of several diseases, but I don't know if this vaccine already exists in our community.”
This KAP study provides valuable insights as the government tries to broaden access to the HPV vaccine next year, and to cervical cancer screening. Understanding hesitancy is key to reaching more girls and women.
Zanzibar’s HPV Plus Model: A Blueprint for Adolescent Health in Africa
In June 2025, delegates from across Eastern and Southern Africa converged in Zanzibar, not just to review data, but to experience a living success story. The island, positioning itself as a Centre of Excellence for Universal Health Coverage, showcased its ; an approach that has redefined adolescent health delivery and increased HPV vaccine coverage.
First piloted in mainland Tanzania and rolled out in Zanzibar in 2023, the model is spearheaded by the Ministry of Health in partnership with the Ministry of Education. It goes beyond simply administering the HPV vaccine, instead embedding it within a comprehensive package of adolescent services, from sexual and reproductive health education to nutrition and even eye care. This holistic approach ensures that every encounter is an opportunity to address the diverse needs of young people. The results have been nothing short of transformative. In just one year, HPV Plus reached over 800 schools and 183 health facilities, with the support of community leaders, known locally as Shehas, who ensured that even out-of-school girls were not left behind. The impact is clear: HPV vaccine coverage leapt from a mere 14% in 2023 to an impressive 85% in 2024, setting a new standard for integrated adolescent health in the region.
This feature was written by Linda Mobula, Abel Ntambue, Alice Ndoko, Hellen Lutta